3-((2-Bromopyridin-3-yl)oxy)-6-chloropyridazine

Catalog No. :
ACKMDX125
CAS No. :
1065484-70-9
Molecular Formula :
C9H5BrClN3O
Molecular Weight :
286.52

IUPAC Name:3-((2-bromopyridin-3-yl)oxy)-6-chloropyridazine

3-((2-Bromopyridin-3-yl)oxy)-6-chloropyridazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$450.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-((2-Bromopyridin-3-yl)oxy)-6-chloropyridazine
IUPAC Name3-((2-bromopyridin-3-yl)oxy)-6-chloropyridazine
MDL No.MFCD10698948
Molecular FormulaC9H5BrClN3O
Molecular Weight286.52
SMILESClC1=NN=C(OC2=CC=CN=C2Br)C=C1
InChI KeyAERSMHFXOLIMOA-UHFFFAOYSA-N
Synonym3-[(2-Bromo-3-pyridinyl)oxy]-6-chloropyridazine;Pyridazine, 3-[(2-bromo-3-pyridinyl)oxy]-6-chloro-;3-(2-BroMo-pyridin-3-yloxy)-6-chloro-pyridazine, 98+% C9H5BrClN3O, MW: 286.52 ISO 9001:2015 REACH;3-(2-Bromo-pyridin-3-yloxy)-6-chloro-pyridazine
CAS No.1065484-70-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACKMDX125 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACNROZ260 route compound structure diagram
    ACNROZ260141-30-0 In Stock
  2. Plus
  3. ACAXYU715 route compound structure diagram
    ACAXYU7156602-32-0 In Stock
  4. Then
  5. ACKMDX125 route product structure diagram
    ACKMDX1251065484-70-9
Inquiry

2. ACKMDX125 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACQFRX407 route compound structure diagram
    ACQFRX40789089-18-9 In Stock
  2. Plus
  3. ACAXYU715 route compound structure diagram
    ACAXYU7156602-32-0 In Stock
  4. Then
  5. ACKMDX125 route product structure diagram
    ACKMDX1251065484-70-9
Inquiry

Comments (0)